14 Nov – Fred Cheng recently celebrated turning 41 by revealing that his focus this year has been on son Asher.
Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish ...
Ultragenyx Pharmaceutical (RARE) shows promising results for GTX-102 in Angelman syndrome Phase 1/2 trial, supporting a Phase ...
Daily Mail on MSN6h
Sir Keir Starmer lauds 'path of change' in speech to Welsh Labour conferenceSir Keir Starmer hailed a "path of change" with Labour governments in Wales and Westminster as he gave his first address to ...
Ultragenyx Pharmaceutical Inc. (RARE) announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its ...
The global Phase 3 Aspire study will enroll approximately 120 patients with Angelman syndrome with a genetically confirmed diagnosis of full maternal UBE3A gene deletion and will include a 48-week ...
GlobalData on MSN9d
Ionis announces design for Phase III trial of Angelman syndrome therapyIonis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.
New preclinical data for candidate ETX201 illustrate its potential as a first-in-class gene therapy for Angelman syndrome. Studies in non-human primates demonstrate safety, biodistribution ...
Hosted on MSN11h
Mike Tyson makes his entrance for fight vs Jake PaulColumbia Sportswear CEO Tim Boyle joins 'Mad Money' host Jim Cramer to discuss why their products are performing better in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback